Neuland Laboratories Limited, a prominent player in the pharmaceutical and active pharmaceutical ingredient (API) manufacturing sector, has announced the closure of its trading window starting from April 1, 2025. This decision is in compliance with the Company’s Insider Trading Code and the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

The trading window closure will remain in effect until 48 hours after the declaration of the company’s financial results for the 4th quarter and financial year ending on March 31, 2025. This restriction applies to all designated persons, including directors, employees, and other connected individuals who are privy to unpublished price-sensitive information (UPSI).

Key Highlights

• Effective Date of Trading Window Closure: April 1, 2025

• Duration of Closure: Until 48 hours after the declaration of Q4 and FY2024-25 results

• Applicability: Applies to all designated persons under the company’s Insider Trading Code

• Reason for Closure: To prevent insider trading ahead of the financial results announcement

Board Meeting for Financial Results

The Board of Directors of Neuland Laboratories Limited is expected to convene a meeting to approve the company’s financial results for the quarter and year ending on March 31, 2025. The exact date of the Board Meeting will be communicated to the stock exchanges in due course.

During this period, all insiders, including key managerial personnel, promoters, and other connected individuals, are prohibited from buying, selling, or dealing in the company’s securities to prevent any misuse of sensitive financial information.

Purpose and Compliance

The closure of the trading window is a mandatory process followed by companies to uphold corporate governance standards and maintain transparency in financial disclosures. By implementing this measure, Neuland Laboratories ensures compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and protects the interests of investors and stakeholders.

Impact on Designated Persons

During the period of closure, all individuals falling under the category of designated persons are prohibited from trading in the company’s equity shares. Any violation of the trading restrictions during the closed window period may result in penalties and disciplinary action under the company’s Insider Trading Policy.

Company Overview

Neuland Laboratories Limited is a leading pharmaceutical company engaged in the manufacturing and supply of Active Pharmaceutical Ingredients (APIs) to global pharmaceutical companies. The company has a strong track record of delivering quality APIs across multiple therapeutic categories, making it a trusted partner for global pharmaceutical firms.

Conclusion

Neuland Laboratories’ announcement regarding the closure of the trading window reflects the company’s commitment to maintaining corporate integrity and compliance with insider trading norms. Investors and designated persons are advised to take note of this announcement and comply with the prescribed guidelines. The company is expected to release its Q4 and FY2024-25 financial results soon after the Board Meeting, with further information to be communicated in due course.

The Upcoming IPOs in this week and coming weeks are Arisinfra Solutions Limited,Identixweb Limited,Retaggio Industries Limited,Infonative Solutions Limited.

The Current active IPO are ATC Energies System Limited, Shri Ahimsa Naturals Limited,Desco Infratech Limited,Rapid Fleet Management Services, Active Infrastructures Limited.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.